RANDOMIZED PHASE II STUDY OF CISPLATIN PLUS RADIOTHERAPY VERSUS DURVALUMAB PLUS RADIOTHERAPY FOLLOWED BY ADJUVANT DURVALUMAB VERSUS DURVALUMAB PLUS RADIOTHERAPY FOLLOWED BY ADJUVANT TREMELIMUMAB AND DURVALUMAB IN INTERMEDIATE RISK HPV-POSITIVE LOCOREGIONALLY ADVANCED OROPHARYNGEAL SQUAMOUS CELL CANCER (LA-OSCC)

Registry ID

HN.9

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY

Start date

2018-04-11

Last update

2018-01-05

Conditions

• OROPHARYNX CANCER

Related clinical trials

• SPECT-CT GUIDED ELECTIVE CONTRALATERAL NECK TREATMENT (SELECT) FOR PATIENTS WITH LATERALIZED OROPHARYNGEAL CANCER: A PHASE III RANDOMIZED CONTROLLED TRIAL
• A FEASIBILITY TRIAL OF LYMPHATIC MAPPING WITH SPECT-CT FOR EVALUATING CONTRALATERAL DISEASE IN LATERALIZED OROPHARYNX CANCER USING 99M-TECHNETIUM SULFUR COLLOID
• INDUCTION CHEMOTHERAPY FOLLOWED BY TRANSORAL ROBOTIC SURGERY AND NECK DISSECTION FOR DEFINITIVE MANAGEMENT OF OROPHARYNGEAL SQUAMOUS CELL CARCINOMA

View on source registry